Fig. 2From: Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registryPercentage change in median PSA over time in (a) all patients; b patients with metastatic disease at baseline; c patients with prior hormonal therapy; and (d) patients with no prior hormonal therapyBack to article page